Logo

German Congress of Orthopaedics and Traumatology 2026 (DKOU 2026)

Deutsche Gesellschaft für Orthopädie und Unfallchirurgie (DGOU), Deutsche Gesellschaft für Orthopädie und Orthopädische Chirurgie (DGOOC), Deutsche Gesellschaft für Unfallchirurgie (DGU), Berufsverband für Orthopädie und Unfallchirurgie (BVOU)
20.-23.10.2026
Berlin

Meeting Abstract

Cyclodextrin-solubilized myrrh oil in injectable GelMA hydrogel for antibacterial bone infection scaffolds

Junwen Zheng - Experimental Trauma Surgery, Faculty of Medicine, Justus-Liebig-University, Gießen, Deutschland
Vahid Jahed - Experimental Trauma Surgery, Faculty of Medicine, Justus-Liebig-University, Gießen, Deutschland
Fatemeh Rastegar Adib - Experimental Trauma Surgery, Faculty of Medicine, Justus-Liebig-University, Gießen, Deutschland
Christian Heiss - Experimental Trauma Surgery, Faculty of Medicine, Justus-Liebig-University, Gießen, Deutschland; Department of Trauma, Hand and Reconstructive Surgery, University Hospital of Gießen-Marburg, Gießen, Deutschland
Thaqif El Khassawna - Experimental Trauma Surgery, Faculty of Medicine, Justus-Liebig-University, Gießen, Deutschland

Text

Objectives and questions: Bone infection (osteomyelitis) is a major complication in orthopaedic surgery and is frequently associated with biofilm formation and antibiotic -resistant strains like methicillin-resistant Staphylococcus aureus (MRSA). While myrrh oil possesses known antibacterial and antioxidant properties, its clinical application is hindered by poor aqueous solubility. This study developed a water-soluble inclusion complex of myrrh oil with hydroxypropyl-β-cyclodextrin (HP-β-CD) and incorporated it into an injectable gelatin methacryloyl (GelMA) hydrogel to create a biocompatible, antibacterial scaffold for localized infection management.

Material and methods: Myrrh oil was extracted via rotary vacuum evaporation and complexed with HP-β-CD to enhance solubility. Antibacterial efficacy of the myrrh–CD complex (0–50% w/v) was evaluated using liquid culture and agar diffusion assays against Escherichia coli, S. aureus, and MRSA. Cytocompatibility was assessed via CCK-8 assays using human-derived stem cells. Antioxidant potential was quantified using the DPPH radical-scavenging assay. Finally, the complex was integrated into a photocrosslinkable GelMA hydrogel (3:1:10 weight ratio) to evaluate the biocompatibility of the 3D formulation.

Results: The myrrh–CD inclusion complex demonstrated significant antibacterial activity at concentrations ≥10% (w/v), achieving >90% reduction in bacterial growth compared to controls (p < 0.01). Agar diffusion assays yielded clear inhibition zones for S. aureus (10.54 mm ± 0.11 mm) and MRSA (10.11 mm ± 0.24 mm). The complex exhibited dose-dependent antioxidant activity, reaching 50% radical scavenging at a concentration of 10% (w/v), while CD alone showed no measurable activity. Cytocompatibility assays confirmed no detectable cytotoxicity, with stem cell viability remaining >90% after 24 hours of exposure to the complex. Furthermore, the GelMA-based 3D hydrogel preserved high cell viability upon direct contact, confirming the maintenance of biocompatibility within the final scaffold formulation.

Discussion and conclusions: Complexation with HP-β-CD successfully solubilizes myrrh oil while preserving its potent antibacterial and antioxidant properties. The resulting myrrh–CD complex shows significant efficacy against resistant strains like MRSA without inducing cytotoxicity in human-derived stem cells. Preliminary incorporation into an injectable GelMA hydrogel maintains high cell viability, supporting its potential as a biocompatible 3D scaffold for the local treatment of bone infections.